BAY 866150

Drug Profile

BAY 866150

Alternative Names: BAY 86-6150; BAY VII; Factor VIIa - Bayer; Maxy 968; MAXY-VII

Latest Information Update: 20 Aug 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Maxygen
  • Developer Bayer HealthCare
  • Class Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Factor VIIa stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haemophilia A; Haemophilia B

Most Recent Events

  • 20 Aug 2013 Discontinued - Phase-I for Haemophilia A in United Kingdom (Parenteral)
  • 20 Aug 2013 Discontinued - Phase-I for Haemophilia B in United Kingdom (Parenteral)
  • 20 Aug 2013 Discontinued - Phase-II/III for Haemophilia A in Bulgaria, Poland, Singapore, South Korea, South Africa and Ukraine (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top